Program
sacituzumab govitecan
Also written as “Sacituzumab Govitecan-hziy”, “Sacituzumab Govitecan” and “Sacituzumab Govitecan-hziy (SG)”.
Its studies are mostly in Triple Negative Breast Neoplasms · Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Carcinoma, Transitional Cell · Neoplasm Metastasis, led by 2 companies.
Drug pageSacituzumab govitecan: every studyAll 102 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciencesits history only | 2317 open or running | phase 4since Mar 19, 2020 | Jun 26, 2012 | Dec 2026phase 1 · NCT04617522 |
| Merckits history only | 11 open or running | phase 3since Nov 2, 2022 | Nov 2, 2022 | Jan 12, 2027phase 3 · NCT05609968 |
Also a collaborator on its studies: Pfizer, Merck KGaA, Darmstadt, Germany and Arcus Biosciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 9 earlier studies, Jun 26, 2012 to Aug 19, 2020.
- Jun 9, 2015Named sacituzumab govitecanINNProposed as its International Nonproprietary Name in WHO's List 113
- Nov 2, 2020Phase 1 study in Neoplasm MetastasisGilead Sciences · NCT04617522 · 30 planned · United States, France, Italy and more
- Nov 17, 2020Phase 3 study in Breast NeoplasmsGilead Sciences · NCT04639986 · 331 enrolled · China, South Korea, Taiwan
- Oct 11, 2021Phase 3 study in Carcinoma, Non-Small-Cell LungGilead Sciences · NCT05089734 · 603 enrolled · United States, Australia, Austria and more
- Oct 19, 2021Phase 2 study in Triple Negative Breast NeoplasmsGilead Sciences · NCT05101096 · 135 enrolled · Japan
- Nov 3, 2021Phase 2 study in Solid TumorGilead Sciences · NCT05119907 · 53 enrolled · China
- Dec 23, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungGilead Sciences · NCT05186974 · 193 enrolled · United States, Australia, Canada and more
- May 16, 20222 phase 3 studies in Triple Negative Breast NeoplasmsGilead Sciences · NCT05382299, NCT05382286
- Nov 2, 2022Merck’s first study: phase 3 study in Carcinoma, Non-Small-Cell LungNew to MerckMerck · NCT05609968 · 614 enrolled · United States, Australia, Brazil and more
- Nov 21, 2022Phase 2 study in Lung NeoplasmsGilead Sciences · NCT05633667 · 192 enrolled · United States, Brazil, Hong Kong and more
- Nov 21, 2022Phase 3 study in Triple Negative Breast NeoplasmsGilead Sciences · NCT05633654 · 1,514 planned · United States, Australia, Belgium and more
- Apr 21, 2023Phase 3 study in Breast NeoplasmsGilead Sciences · NCT05840211 · 654 enrolled · United States, Argentina, Australia and more
- Jun 27, 2024Phase 3 study in Endometrial NeoplasmsGilead Sciences · NCT06486441 · 640 enrolled · United States, Australia, Brazil and more
- Jan 24, 2025Phase 3 study in Extensive Stage Small Cell Lung Cancer (ES-SCLC)Gilead Sciences · NCT06801834 · 695 planned · United States, Argentina, Australia and more
- Apr 8, 2025Phase 2 study in Triple Negative Breast NeoplasmsGilead Sciences · NCT06926920 · 100 planned · United States, Australia, South Korea
Ahead
- Dec 2026Primary completion: phase 3 study in Breast NeoplasmsGilead Sciences · NCT04639986
- Dec 2026Primary completion: phase 1 study in Neoplasm MetastasisGilead Sciences · NCT04617522
- Jan 12, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungMerck · NCT05609968
- Feb 2027Primary completion: phase 3 study in Triple Negative Breast NeoplasmsGilead Sciences · NCT05382286
TargetBeta
“Tumor-associated calcium signal transducer 2 binding agent”ChEMBL 37, by rule
Other programs on TACSTD2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sacituzumab tirumotecan | Merck | phase 3 | 50 |
| datopotamab deruxtecanrule | AstraZeneca | phase 3 | 29 |
| JSKN016rule | Alphamab Oncology | phase 3 | 5 |
| Anti-TROP2 Antibody-drug Conjugate ESG401rule | Qilu Pharmaceutical | phase 3 | 3 |
| Anti-TROP-2/Topoisomerase Inhibitor ADC MHB036Crule | Minghui Pharmaceutical | phase 2 | 3 |
| sacituzumab drozuntecanrule | dualitybio-inc | phase 2 | 2 |
| Anti-TROP-2 Antibody-drug Conjugate OBI-902rule | obi-pharma-inc | phase 2 | 1 |
| Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103rule | avenzo-therapeutics-inc | phase 2 | 1 |
| Anti-TROP2/Topoisomerase I Inhibitor-STING Agonist Immunostimulatory ADC ASP2998rule | Astellas Pharma | phase 2 | 1 |
| JSKN016HCrule | Alphamab Oncology | phase 1 | 1 |
| KH815rule | Chengdu Kanghong Pharmaceutical Group | phase 1 | 1 |
Studies
All 24 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06926920Triple Negative Breast Neoplasms · United States, Australia, South Korea | 2 | Recruiting | Gilead Sciences | Jun 2028 | 100 |
| NCT06801834Extensive Stage Small Cell Lung Cancer (ES-SCLC) · United States, Argentina, Australia and more | 3 | Recruiting | Gilead Sciences | Oct 2029 | 695 |
| NCT06486441Endometrial Neoplasms · United States, Australia, Brazil and more | 3 | Active, not recruiting | Gilead Sciences | Jun 2029 | 640 |
| NCT05840211Breast Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Gilead Sciences | Apr 2028 | 654 |
| NCT05633667Lung Neoplasms · United States, Brazil, Hong Kong and more | 2 | Active, not recruiting | Gilead Sciences | Sep 2029 | 192 |
| NCT05633654Triple Negative Breast Neoplasms · United States, Australia, Belgium and more | 3 | Recruiting | Gilead Sciences | Jun 2027 | 1,514 |
| NCT05609968Carcinoma, Non-Small-Cell Lung · United States, Australia, Brazil and more | 3 | Active, not recruiting | Merck | Jan 12, 2027 | 614 |
| NCT05382299Triple Negative Breast Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Gilead Sciences | Jul 2028 | 623 |
| NCT05382286Triple Negative Breast Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Gilead Sciences | Feb 2027 | 443 |
| NCT05186974Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more | 2 | Active, not recruiting | Gilead Sciences | Mar 2027 | 193 |
| NCT05119907Solid Tumor · China | 2 | Active, not recruiting | Gilead Sciences | Oct 2026 | 53 |
| NCT05101096Triple Negative Breast Neoplasms · Japan | 2 | Active, not recruiting | Gilead Sciences | May 2027 | 135 |
| NCT05089734Carcinoma, Non-Small-Cell Lung · United States, Australia, Austria and more | 3 | Active, not recruiting | Gilead Sciences | Nov 29, 2023 | 603 |
| NCT04639986Breast Neoplasms · China, South Korea, Taiwan | 3 | Active, not recruiting | Gilead Sciences | Dec 2026 | 331 |
| NCT04617522Neoplasm Metastasis · United States, France, Italy and more | 1 | Recruiting | Gilead Sciences | Dec 2026 | 30 |
| NCT04527991Locally Advanced or Metastatic Unresectable Urothelial Cancer · United States, Australia, Austria and more | 3 | Completed | Gilead Sciences | Jul 4, 2025 | 711 |
| NCT04454437Triple Negative Breast Neoplasms · China | 2 | Active, not recruiting | Gilead Sciences | Aug 6, 2021 | 80 |
| NCT04319198Metastatic Solid Tumors · United States, Belgium, France | 4 | Completed | Gilead Sciences | Oct 18, 2024 | 25 |
| NCT03964727Neoplasm Metastasis · United States, Australia, Belgium and more | 2 | Active, not recruiting | Gilead Sciences | Jan 15, 2025 | 227 |
| NCT03901339Breast Neoplasms · United States, Belgium, Canada and more | 3 | Completed | Gilead Sciences | Oct 20, 2023 | 543 |
| NCT03547973Metastatic Urothelial Cancer · United States, France, Germany and more | 2 | Active, not recruiting | Gilead Sciences | Apr 2030 | 502 |
| NCT02574455Breast Neoplasms · United States, Belgium, Canada and more | 3 | Completed | Gilead Sciences | Mar 30, 2020 | 529 |
| NCT02161679Triple Negative Breast Neoplasms | 2 | Withdrawn | Gilead Sciences | Aug 2016 | 0 |
| NCT01631552Esophageal Neoplasms · United States | 2 | Completed | Gilead Sciences | Mar 1, 2019 | 515 |
How it is read
Names in the registry
- “Sacituzumab Govitecan-hziy”, 12 entries
- “Sacituzumab Govitecan”, 4 entries
- “Sacituzumab Govitecan-hziy (SG)”, 4 entries
- “Sacituzumab govitecan-hziy (SG)”, 2 entries
- “Sacituzumab Govitecan (SG)”, 2 entries
Conditions, from the studies’ own filings
- Triple Negative Breast Neoplasms, 7 studies
- Breast Neoplasms, 5 studies
- Carcinoma, Non-Small-Cell Lung, 5 studies
- Carcinoma, Transitional Cell, 2 studies
- Neoplasm Metastasis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.